Last reviewed · How we verify
insulin glargine and insulin aspart — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
insulin glargine and insulin aspart (insulin glargine and insulin aspart) — Dr. Muhammad Abdulghani.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| insulin glargine and insulin aspart TARGET | insulin glargine and insulin aspart | Dr. Muhammad Abdulghani | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- insulin glargine and insulin aspart CI watch — RSS
- insulin glargine and insulin aspart CI watch — Atom
- insulin glargine and insulin aspart CI watch — JSON
- insulin glargine and insulin aspart alone — RSS
Cite this brief
Drug Landscape (2026). insulin glargine and insulin aspart — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glargine-and-insulin-aspart. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab